SPARC slips 10% as USFDA rejects cancer drug application

The company has received a Complete Response Letter (CRL) from the USFDA for the new drug application (NDA) for Taclantis (Paclitaxel Injection Concentrate for Suspension).

Premium

Photo: Shutterstock

SI Reporter Mumbai

2 min read Last Updated : Feb 12 2020 | 11:15 AM IST

Shares of Sun Pharma Advanced Research Company (SPARC) slipped 10 per cent to Rs 172 on the BSE on Wednesday in an otherwise strong market after the US health regulator rejected the cancer drug application.

SPARC on Tuesday said the company has received a Complete Response Letter (CRL) from the United States Food & Drug Administration (USFDA) for the new drug application (NDA) for Taclantis (Paclitaxel Injection Concentrate for Suspension).

The company is reviewing the CRL and intends to work with the USFDA as soon as possible to address the concerns raised, it added.

Abraxane is indicated

Topics : SPARC Sun Pharma Advanced Research SPARC Buzzing stocks

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in